What happened Shares of BioCryst (BCRX 0.00%), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. A drop in top-line revenue and softer-than-expected guidance aren't sitting well with investors, who have driven the stock 16.5% lower as of 11:50 a.m. on Wednesday.
Full Answer
Where can I buy BLRX stock?
Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is BLRX a sell or buy at Robinhood?
Today BLRX ranks #13644 as sell candidate. Get a Free Stock at Robinhood Which way will BLRX go? * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
Do analysts agree on BioLineRx's (BLRX) price target?
The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts' consensus price target of $14.50, BioLineRx has a forecasted upside of 692.3% from its current price of $1.83.
Is BioLineRx's stock a buy for dividend growth?
BioLineRx does not have a long track record of dividend growth. In the past three months, BioLineRx insiders have not sold or bought any company stock. Only 1.10% of the stock of BioLineRx is held by insiders. Only 5.10% of the stock of BioLineRx is held by institutions.
Is BLRX a good stock to buy?
Is BIOLINERX Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: BLRX) stock is to Strong Buy BLRX stock.
Is BLRX a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Is Biolinerx stock a buy?
BioLine RX Ltd (NASDAQ:BLRX) The 3 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 10.00, with a high estimate of 19.00 and a low estimate of 7.25. The median estimate represents a +681.25% increase from the last price of 1.28.
Is BioLine RX a buy ?>?
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Are investors shorting BioLineRx?
BioLineRx saw a increase in short interest in May. As of May 15th, there was short interest totaling 477,400 shares, an increase of 30.8% from the...
When is BioLineRx's next earnings date?
BioLineRx is scheduled to release its next quarterly earnings announcement on Wednesday, August 17th 2022. View our earnings forecast for BioLineRx .
How were BioLineRx's earnings last quarter?
BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.10) earnings per...
Who are BioLineRx's key executives?
BioLineRx's management team includes the following people: Mr. Philip A. Serlin CPA , M.B.A., CPA, MBA, Chief Exec. Officer (Age 62, Pay $644k)...
Who are some of BioLineRx's key competitors?
Some companies that are related to BioLineRx include Edgewise Therapeutics (EWTX) , Silence Therapeutics (SLN) , Seres Therapeutics (MCRB) , In...
What other stocks do shareholders of BioLineRx own?
Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB) ,...
What is BioLineRx's stock symbol?
BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."
Who are BioLineRx's major shareholders?
BioLineRx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Parkman Healthcare Partners...
Which major investors are selling BioLineRx stock?
BLRX stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, Envestnet Asset Managem...